Blue water biotech expands commercial portfolio by acquiring six fda-approved drugs across various treatment areas

Cincinnati, ohio, june 14, 2023 (globe newswire) -- blue water biotech, inc. (nasdaq: bwv), a biotechnology company spanning multiple sectors, today announced the signing of an asset purchase agreement (the “agreement”) with wraser, llc and xspire pharma, llc (together, “wraser”) for the purchase of six fda-approved assets across multiple indications, including cardiology, otic infections, and pain management (the “wraser assets”).
BWV Ratings Summary
BWV Quant Ranking